| | |
Univariate
|
Multivariate
|
|---|
| | |
Hazard ratio
|
(95 % CI)
|
P-value
|
Hazard ratio
|
(95 % CI)
|
P-value
|
|---|
|
Progression-free survival
|
|
EILD
|
Yes
|
1.80
| |
0.013
|
1.44
| |
0.16
|
| |
No
| |
1.11–2.88
| | |
0.86–2.41
| |
|
Age
| ≦56≦56 |
0.76
| |
0.14
|
0.76
| |
0.19
|
| |
>56
| |
0.52–1.10
| | |
0.51–1.15
| |
|
PS
|
0
|
1.41
| |
0.089
|
1.49
| |
0.073
|
| |
1,2
| |
0.95–2.10
| | |
0.96–2.31
| |
|
Comorbid disease
|
Yes
|
1.44
| |
0.12
|
1.51
| |
0.13
|
| |
No
| |
0.91–2.28
| | |
0.88–2.58
| |
|
DFI
| ≦2.8≦2.8 |
1.41
| |
0.069
|
1.27
| |
0.27
|
| |
>2.8
| |
0.97–2.06
| | |
0.83–1.95
| |
|
BMI
|
>25
|
1.64
| |
0.036
|
1.22
| |
0.47
|
| | ≦25≦25 | |
1.03–2.59
| | |
0.71–2.07
| |
|
HR (ER/PgR) status
|
Positive
|
1.49
| |
0.062
|
1.25
| |
0.37
|
| |
Negative
| |
0.98–2.28
| | |
0.77–2.03
| |
|
HER2 status
|
Negative
|
1.60
| |
0.067
|
1.32
| |
0.30
|
| |
Positive
| |
0.97–2.65
| | |
0.77–2.26
| |
|
Liver metastasis
|
No
|
0.95
| |
0.067
|
0.93
| |
0.72
|
| |
Yes
| |
0.65–1.38
| | |
0.63–1.38
| |
|
Overall survival
|
|
EILD
|
Yes
|
2.22
| |
0.038
|
1.75
| |
0.17
|
| |
No
| |
1.05–4.71
| | |
0.78–3.91
| |
|
Age
| ≦56≦56 |
0.81
| |
0.45
|
0.77
| |
0.37
|
| |
>56
| |
0.47–1.39
| | |
0.43–1.36
| |
|
PS
|
0
|
2.34
| |
0.0021
|
2.37
| |
0.0039
|
| |
1,2
| |
1.36–4.03
| | |
1.32–4.26
| |
|
Comorbid disease
|
Yes
|
0.91
| |
0.77
|
1.04
| |
0.91
|
| |
No
| |
0.49–1.70
| | |
0.51–2.13
| |
|
DFI
| ≦2.8≦2.8 |
1.78
| |
0.038
|
1.53
| |
0.18
|
| |
>2.8
| |
1.03–3.07
| | |
0.83–2.85
| |
|
BMI
|
>25
|
1.33
| |
0.39
|
1.13
| |
0.75
|
| | ≦25≦25 | |
0.69–2.52
| | |
0.55–2.31
| |
|
HR (ER/PgR) status
|
Positive
|
1.67
| |
0.089
|
1.15
| |
0.70
|
| |
Negative
| |
0.93–3.01
| | |
0.57–2.29
| |
|
HER2 status
|
Negative
|
1.87
| |
0.093
|
1.42
| |
0.39
|
| |
Positive
| |
0.90–3.88
| | |
0.64–3.16
| |
|
Liver metastasis
|
No
|
0.96
| |
0.89
|
1.00
| |
0.99
|
| |
Yes
| |
0.56–1.64
| | |
0.56–1.79
| |
- Abbreviation: 95 % CI 95 % confidence interval, EILD eribulin-induced liver dysfunction, PS performance status, DFI disease free interval, BMI body mass index, HR hormone receptor, ER estrogen receptor, PgR progesterone receptor, HER2 human epidermal growth factor receptor 2
